CP and COVID-19: In December 2021, the U.S. FDA revised these guidelines, suggesting the use of COVID‐19 CP for patients with immunosuppressive diseases or those receiving immunosuppressive treatment, with a preference for CP with high neutralizing antibody (nAb) titers.12, 32